Meibai Bio Secures Tens of Millions in Series A+ Financing to Lead Global Industrialization of Human Cell-Derived ECM Regenerative Biomaterials

In recent years, regenerative medicine has witnessed robust growth momentum, with the extracellular matrix (ECM) With its excellent repair and guided regeneration capabilities as well as biocompatibility, it firmly holds the top position among regenerative materials.

VCBeat Exclusively Learns: MAYBIO, the First Enterprise in China to Efficiently Produce ECM Composite Collagen Using Human Cell-Based In Vitro Tissue Engineering Technology, Completes Tens of Millions of RMB in A+ Round FinancingBeijing Maybio Pharmaceutical Biotechnology Development Co., Ltd. (hereinafter referred to as “MAYBIO”), the first enterprise in China to efficiently produce ECM composite collagen using human cell-based in vitro tissue engineering technology, has recently completed an A+ round financing amounting to tens of millions of RMB. This round of financing was jointly invested by Guangdong Sunz Investment Management CO.,LTD, Hunan Caixin Fund Management Co.,Ltd, and Beijing New Airport City Fund, with Sinohope Capital serving as the continuous financial advisor. Upon completion of this financing round, MAYBIO will accelerate the capacity expansion of raw materials such as human-derived extracellular matrix collagen and the clinical registration of Class III medical devices.

MAYBIO is dedicated to the research and development, production, and sales of high-performance biologic scaffolds for maxillofacial regeneration. As an innovative enterprise, it provides regenerative biologic scaffold materials to meet the clinical needs of medical aesthetics in the repair of maxillofacial defects and deformities. The company was founded by a postdoctoral fellow from the University of Pennsylvania and a M.D. from Peking University Health Science Center.Xiao E, Distinguished Researcher at the College of Polymer Science and Engineering, Sichuan University; Ph.D., Freie Universität BerlinWei Qiangand the MBA program at Paris 1 Panthéon-Sorbonne UniversityMs. Mei JinzhuoCo-founded.

Leveraging years of technological accumulation, MAYBIO innovatively utilizes human-derived engineered cells as expression vectors to achieve targeted, high-efficiency in vitro expression of extracellular matrix components. By combining crosslinker-free crosslinking technology with polymeric materials, the company has achieved mass production of bioinductive hydrogels that remodel the cellular microenvironment and fundamentally repair tissue damage.

Leveraging the production advantages of human-derived extracellular matrix (ECM) technology, the company has launched the Meiweiti-Ya, Yao, and Nuo product series for maxillofacial aesthetic restoration and regeneration. Meanwhile, it has established a pre-filled syringe sterile processing production line to ensure that active substances such as collagen retain their biological activity during processing.

After years of dedication,MAYBIO hasA pre-filled syringe sterile processing production line has been established in the Liuyang Economic and Technological Development Zone in Changsha, with an annual capacity of 800,000 units of sterile gel and an output value of nearly RMB 1 billion. It is currently the largest R&D and industrial base for human-derived ECM in China.

Meiweiti-Ya Series

MAYBIO Production Line

Leveraging its innovative product capabilities and stable production capacity, MAYBIO has established collaborations with numerous renowned pharmaceutical companies and medical institutions, and has repeatedly achieved outstanding results in major competitions.

• The company’s product (Medical Recombinant Humanized Collagen Gel Dressing/Type WD-II) was included in the 2022 “Hunan Provincial Industrial New Products” (First Batch) list;

• Awarded Top 100 Most Innovative Medical Technology Products (Solutions) at the 2022 VB-Find Awards;

• The company’s startup project was awarded the title of “2022 Most Promising Overseas Returnee Entrepreneurial Enterprise” by the Ministry of Human Resources and Social Security;

• The company’s founding team has been recognized as the “Changsha Overseas Science and Technology Innovation and Entrepreneurship Team.”

• Founder Dr. Xiao E was selected for the Chang“Shashi High-End Talent Leading Program”；

• Dr. Xiao E, the founder, was selected as a “2023 Hunan Youth Talent (Technology Innovation Category)”）”；
  

• Dr. Wei Qiang, the founder, was selected for the Hunan High-Level Talent Aggregation Project;

• Dr. Wei Qiang, the founder, was honored as the Outstanding Young Scientist of the Year in Translation by VCBeat’s VB-Link Award;

It is worth noting that in January this year, MAYBIO, in collaboration with *Dermatologic Surgery*, the official publication of the American Society for Dermatologic Surgery, released a special issue on Extracellular Matrix (ECM) in China. The issue featured invited experts from both domestic and international communities to conduct thematic discussions on the application of ECM in skin tissue regeneration. This fully demonstrates the international academic community’s recognition of MAYBIO’s clinical value in this field, showcasing its international academic strength and breakthrough therapeutic value.

Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery (ASDS), the American College of Mohs Surgery, the International Society of Hair Restoration Surgery, and the International Alliance of Aesthetic Plastic Surgeons.

Regarding the company's future development,Xiao E, Founder of MAYBIOIt was stated that future marketing strategies for MAYBIO will focus on the human extracellular matrix (ECM) product category, establishing an academic science popularization system under the brand—MAYBIO ECM Academy. The company will prioritize product education for healthcare professionals and comprehensively promote and build medical sales channels. Building on existing foundations, MAYBIO will develop premium flagship products within the Meiweiti series, continuously optimizing and enhancing their performance. Additionally, the company will improve services for distributors and institutions to rapidly establish brand equity, laying the groundwork for the nationwide rollout of its distributor network.

To ensure the forward-looking nature and innovativeness of R&D, the company also collaborates withCentral South University, Hunan University, Sichuan University, Nanjing Universitycollaborate with renowned universities on industry-academia-research projects, and withPeking Union Medical College Hospital, Xiangya Hospital of Central South UniversityLaunch clinical research collaborations to foster synergistic innovation among industry, academia, research, and healthcare. Recently, the Meiweiti-Ya product for maxillofacial deformity repair has passed the clinical review at Xiangya Hospital, and clinical trials for maxillofacial reconstruction are set to commence at the hospital shortly.

It is reported that Beijing MAYBIO Pharmaceutical Biotechnology Development Co., Ltd. has established its presence in the Daxing Airport Economic Zone. Leveraging the world’s largest hub airport, the Daxing Airport Economic Zone has defined a “1+2+2” industrial system strategic layout led by the life and health industry. It focuses on frontier medical technology fields such as cell and gene technologies and high-value medical devices, striving to build a medical innovation demonstration zone characterized by the “integration of medicine, healthcare, and pharmaceuticals,” with medical research as the core link, and medical services and the pharmaceutical industry as pillars.

Zeng Wenbing, Founding Partner of Sunz Venture CapitalMAYBIO boasts the world’s first medical-grade collagen derived from extracellular matrix (ECM), featuring an intact, full-chain triple-helix structure that holds significant clinical value for medical aesthetics and regenerative medicine applications. The founding team demonstrates strong complementarity. Dr. Xiao E, the founder, efficiently expresses ECM collagen using human cell-based in vitro tissue engineering technology. By integrating this with Dr. Wei Qiang, a biomaterials scientist’s, expertise in cross-linking and intracellular structural mechanics, the team has developed a collagen gel with excellent biomechanical properties within the human body, while ensuring the preservation of the collagen’s triple-helix structural integrity and functional activity. Partner Ms. Mei Zhuojin brings years of experience working with multinational pharmaceutical companies and medical aesthetic institutions, along with a successful entrepreneurial track record. Her extensive academic and medical aesthetic channel resources have paved the way for MAYBIO’s product clinical registration and market launch.

Tang Peihui, Deputy General Manager of Caixin Economic Investmentstated that we are optimistic about the application prospects of extracellular matrix (ECM) in fields such as regenerative medicine and medical aesthetics, and are confident in the industrialization of the company’s in vitro tissue engineering technology and human-derived ECM collagen raw materials. In the future, we will base ourselves in Hunan, integrate industrial and financial resources, and continue to support the company’s long-term development.

Wu Xu, Senior Vice President of Investment at New Airport City FundSameIt stated that regenerative medicine, as a frontier in life and health, is one of the key industries focused on by the New Airport City Fund. MAYBIO possesses significant technological advantages. In the current context of increasing homogenization of upstream raw materials in the medical aesthetics industry, we believe that MAYBIO is poised to become an innovator and reformer in the field of medical aesthetic raw materials, leveraging its fully human-derived collagen materials.

Established in 2008, Sunz Investment Management is a council member of the Venture Capital Professional Committee of the China Association of Investment and a council member of the Medicine Chamber of Commerce of the All-China Federation of Industry and Commerce. It also serves as a vice-president unit of the Guangdong Venture Capital Promotion Association and the Hunan Equity Investment Association. The company focuses on investing in forward-looking sectors such as healthcare and technological innovation, covering multiple stages including startup, growth, and development phases. It has built a comprehensive investment operation and management ecosystem. Sunz Investment Management has been recognized as one of the "Top 100 Best Venture Capital Firms in China" by Zero2IPO Research, one of the "Top 30 Best Healthcare Investment Firms in China," one of the "Top 50 Best VC Funds in China," and one of the "Top 50 VC Funds for Best Returns" by the China Fund of Funds Alliance. Additionally, it was listed among the "Top 10 Most Influential Private Equity Firms in Hunan" and received the "Best VC Firm" award at the Securities Times China Venture Capital Golden Eagle Awards. Committed to providing personalized value-added services in investment operations to its portfolio companies, Sunz Investment Management adheres to the philosophy of "Sunz Creates All Things, Nourishing All Lives," and is dedicated to safeguarding corporate development.

Caixin Industrial Fund is a key private equity investment platform under Caixin Financial Holdings, the only provincial state-owned financial holding group in Hunan Province. It is deeply engaged in Hunan’s economic development and industrial upgrading, with investment focus areas including new energy and new materials, biopharmaceuticals, advanced equipment manufacturing, and next-generation information technology. Leveraging local resources and its comprehensive financial license advantages, the fund provides investee companies with integrated financial services throughout their entire lifecycle.

New Airport City Fund is a professional fund management company focused on industrial investment in the Daxing International Airport Economic Zone. The fund concentrates on the zone’s leading industries, actively investing in life and health, intelligent manufacturing, and next-generation information technology. As infrastructure projects such as the Medical Device Park and Regenerative Medicine Park within the airport economic zone are progressively developed, New Airport City Fund has strategically invested in multiple industry-leading enterprises in these fields, aiming to build a robust industrial ecosystem cluster in the zone.